Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/23/2022 | — | Ladenburg Thalmann | Downgrades | Buy → Neutral | |
05/27/2022 | 426.32% | Ladenburg Thalmann | → $8 | Initiates Coverage On | → Buy |
Allarity Therapeutics Questions & Answers
The latest price target for Allarity Therapeutics (NASDAQ: ALLR) was reported by Ladenburg Thalmann on August 23, 2022. The analyst firm set a price target for $0.00 expecting ALLR to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Allarity Therapeutics (NASDAQ: ALLR) was provided by Ladenburg Thalmann, and Allarity Therapeutics downgraded their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allarity Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allarity Therapeutics was filed on August 23, 2022 so you should expect the next rating to be made available sometime around August 23, 2023.
While ratings are subjective and will change, the latest Allarity Therapeutics (ALLR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Allarity Therapeutics (ALLR) is trading at is $1.52, which is out of the analyst's predicted range.